Pharma BD Deal Intelligence
Nurofen and Strepsils became durable Reckitt "powerbrands" still growing double digits two decades later; Clearasil proved non-core and was shopped for divestiture, and Nurofen carried a real reputational/legal scar from the Australian "Specific Pain" mislabeling case.
Full analysis, sources & comparables →Reckitt is paying 3.6 times sales and 20 times EBITDA versus 2.5-3 times sales and about 14 times EBITDA on comparable sector deals; analysts had not expected…
October 2005 BHI announcement framed as a strategic pivot into branded OTC pharma — explicitly the structural foundation for Reckitt's subsequent Adams…
Case No COMP/M.4007 Reckitt Benckiser / Boots Healthcare International, Regulation (EC) No 139/2004 merger procedure: Article 6(1)(b) non-opposition decision…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Reckitt Benckiser acquires Boots OTC business for £1.9B (~$3.4B). Adds Nurofen, Strepsils, Clearasil to consumer health portfolio.
Nurofen and Strepsils became durable Reckitt "powerbrands" still growing double digits two decades later; Clearasil proved non-core and was shopped for divestiture, and Nurofen carried a real reputational/legal scar from the Australian "Specific Pain" mislabeling case.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Reckitt Benckiser plc / Boots Healthcare International (this deal) | 2005 | $3.4B | 78 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. | 2007 | $2.3B | 82 |
| Reckitt Benckiser plc / Schiff Nutrition International, Inc. | 2012 | $1.4B | 67 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |